Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | FABP3 | P05413 | 9/20 | 0.41 |
| ▸ | FABP4 | P15090 | 6/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 6/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.39 |
| ▸ | SNCA | P37840 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8320734 | 0.94 | ADORA1 (0.44) | ADORA1FABP3FABP4S1PR5 | |
| SCHEMBL7521598 | 0.88 | ADORA1 (0.45) | ADORA1 | |
| SCHEMBL7518668 | 0.82 | ADORA1 (0.41) | ADORA1 | |
| SCHEMBL7526545 | 0.80 | ADORA1 (0.38) | ADORA1FABP3FABP4S1PR5FFAR4 | |
| SCHEMBL7528838 | 0.80 | ADORA1 (0.39) | ADORA1FABP3FABP4S1PR5FFAR4 | |
| SCHEMBL7526025 | 0.78 | KDM4E (0.42) | ADORA1 | |
| SCHEMBL7974210 | 0.76 | ADORA1 (0.41) | ADORA1FABP4 | |
| SCHEMBL7518636 | 0.74 | ALDH1A1 (0.41) | ADORA1 | |
| SCHEMBL7520497 | 0.74 | ADORA1 (0.40) | ADORA1FABP3FABP4S1PR5 | |
| SCHEMBL7522397 | 0.72 | ADORA1 (0.38) | ADORA1FABP3FABP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6417213-B2 | ANTICOAGULANTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-07-09 | — | — | US | disclosed |
| US-20020006944-A1 | Tricyclic compounds, their production and use | OHKAWA SHIGENORI (JP) | 2002-01-17 | — | — | US | disclosed |
| US-6248766-B1 | CARDIOVASCULAR DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006944-A1 | Tricyclic compounds, their production and use | CNR1, PTGER1, PTGDR | ADORA1 210/4885FABP3 2512/4885FABP4 3301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.